Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 Modulator, at AACR 2026

Data highlight biomarker-linked activity and in vivo efficacy of STX-6398, supporting small-molecule CKAP2 modulation as a novel therapeutic approach in cancer SOUTH SAN FRANCISCO, Calif., April 17, 2026  — Soley Therapeutics, a biotechnology company advancing novel therapeutics informed by integrated cell stress biology, today announced the presentation of new preclinical data at the American Association […]

Soley Therapeutics to Unveil a First-in-Class Small Molecule CKAP2 Modulator with Selective Anti-Tumor Activity at AACR 2026

Preclinical data demonstrate how Soley’s proprietary drug discovery platform translates cell stress biology into first-in-class drug candidates SOUTH SAN FRANCISCO, Calif., March 17, 2026 — Soley Therapeutics, a biotechnology company advancing novel therapeutics informed by integrated cell stress biology, today introduced STX-6398, a first-in-class drug candidate with selective anti-tumor activity through modulation of cytoskeleton-associated protein 2 […]

Soley Therapeutics Announces Breakthrough Research Demonstrating How Cellular Stress Responses Reveal Drug Mechanisms, Enabling Entirely New and Accelerated Methods for Drug Discovery

Research published in Scientific Reports highlights novel “Live Cell Dynamics” approach for capturing and analyzing how living cells sense and respond to drugs over time SOUTH SAN FRANCISCO, Calif., January 21, 2026 — Soley Therapeutics today announced the publication of a peer-reviewed study in Scientific Reports describing a new approach to understanding how living cells […]